ELYM ELIEM THERAPEUTICS INC

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

SEATTLE and CAMBRIDGE, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences.

Guggenheim’s 4th Annual Immunology and Neurology Conference

Fireside Chat Date: November 15, 2022

Fireside Chat Time: 10:10 a.m. ET

Location: St. Regis Hotel, New York, NY

Stifel 2022 Healthcare Conference

Fireside Chat date: Wednesday, November 16, 2022

Fireside Chat time: 1:50 p.m. ET

Location: Lotte New York Palace Hotel, New York, NY

A live webcast of the fireside chat presentations will be available on the Investors section of the Eliem Therapeutics website at . An archived replay of each of the events will remain available on Eliem’s website for at least 30 days after the event.

About Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.

Investors

Chris Brinzey

ICR Westwicke



339-970-2843

Media

Marites Coulter

Verge Scientific



415.819.2214



EN
08/11/2022

Underlying

ELYMELIEM THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ELIEM THERAPEUTICS INC

 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4...

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the Company has granted an inducement equity award to a new employee, pursuant to the Company’s 2025 Inducement Plan, as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity award was granted to one n...

May 19, 2025 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio Reports First Quarter 2025 Financial Results and Provides Bu...

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025 CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025 Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer Strong Financial Position, with Cash Runway Expected Through 2027 WELLESLEY HILLS, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Cli...

May 14, 2025 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. “We are delighted to welcome Kim and Bo to our Board of Directors at Climb B...

April 1, 2025 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Con...

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held virtually April 7-10, 2025. 24th Annual Needham Virtual Healthcare Conference Format: Presentation and one-on-one investor meetingsDate: April 10, 2025Time: 8:45 a.m. ETWebcast:  About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with im...

March 27, 2025 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results a...

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) Completed Studies to Support Process Optimization through Cell Line Switch for Budoprutug and Filed Additional Patent Applications to Further Strengthen Intellectual Property Position Expanded Pipeline to Include CLYM116, an Anti-APRIL (A PRoliferation-Inducing Ligand) Monoc...

March 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch